Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 20;8(4):e1001.
doi: 10.1212/NXI.0000000000001001. Print 2021 Jul.

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review

Mahdi Barzegar  1 , Omid Mirmosayyeb  1 , Mahsa Gajarzadeh  1 , Alireza Afshari-Safavi  1 , Nasim Nehzat  1 , Saeed Vaheb  1 , Vahid Shaygannejad  2 , Amir-Hadi Maghzi  1
Affiliations

COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review

Mahdi Barzegar et al. Neurol Neuroimmunol Neuroinflamm. .

Erratum in

Abstract

Objective: We systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS).

Methods: We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19.

Results: From an initial 2,679 publications and 3,138 conference abstracts, 87 studies (67 published articles and 20 abstracts) consisting of 4,310 patients with suspected/confirmed COVID-19 with MS met the inclusion criteria. The female/male ratio was 2.53:1, the mean (SD) age was 44.91 (4.31) years, the mean disease duration was 12.46 (2.27), the mean Expanded Disability Status Scale score was 2.54 (0.81), the relapsing/progressive ratio was 4.75:1, and 32.9% of patients had at least 1 comorbidity. The most common symptoms were fever (68.8%), followed by cough (63.9%), fatigue/asthenia (51.2%), and shortness of breath (39.5%). In total, 837 of 4,043 patients with MS with suspected/confirmed COVID-19 (20.7%) required hospitalization, and 130 of 4,310 (3.0%) died of COVID-19. Among suspected/confirmed patients, the highest hospitalization and mortality rates were in patients with no disease-modifying therapies (42.9% and 8.4%), followed by B cell-depleting agents (29.2% and 2.5%).

Conclusion: Our study suggested that MS did not significantly increase the mortality rate from COVID-19. These data should be interpreted with caution as patients with MS are more likely female and younger compared with the general population where age and male sex seem to be risk factors for worse disease outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flowchart of the Study
See this image and copyright information in PMC

References

    1. Wijnands JM, Kingwell E, Zhu F, et al. . Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler J 2017;23:1506–1516. - PubMed
    1. Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018;5:ofy174. - PMC - PubMed
    1. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 2013;20:1153–1160. - PubMed
    1. Nelson RE, Xie Y, DuVall SL, et al. . Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care 2015;17:221–230. - PMC - PubMed
    1. OWorld Health Organization. Coronavirus Disease (COVID-19) Outbreak. Accessed September 18, 2020. who.int

Publication types